Drug Profile
Research programme: anti-cancer therapeutics - Oncurious/VIB
Alternative Names: CCR8 Treg program - Oncurious/VIBLatest Information Update: 18 Mar 2020
Price :
$50
*
At a glance
- Originator VIB
- Developer Oncurious
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer